Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Daiichi Sankyo, Inc., Seattle Genetics, and Takeda Oncology.

T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL

Release Date: December 21, 2020
Expiration Date: December 21, 2021

Activity Overview

T-cell lymphomas (TCLs) are a group of non-Hodgkin lymphomas (NHLs) that account for approximately 5% to 20% of all NHL cases in Western countries. The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge related to TCL therapeutics have continued to create practice and/or educational gaps for oncologists and the multidisciplinary team who strive to maintain state-of-the-art care and counseling for their patients. In addition to these therapeutic advances, the past several years have brought advances in understanding the pathobiology of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) and their management. These advances have resulted in a shift to personalized strategies that recognize these tumors as a heterogeneous group of diseases.

The T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL webcast gives oncology health care providers expert perspectives on the molecular pathogenesis of PTCL and CTCL and their diagnosis and treatment. The renowned faculty discusses optimization of currently available therapies and emerging trends in new treatments. The webcast features a multidisciplinary panel of hematology experts discussing cases, analyzing the integration of lab results into clinical practice, and reviewing the application of novel agents in individualized patient care.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Daiichi Sankyo, Inc., Seattle Genetics, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with TCLs. Fellows, researchers, nurses, nurse practitioners, physician assistants, dermatologic oncologists, dermatologists, and other health care professionals interested in the treatment of patients with TCLs are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss specific disease subtypes of TCLs and the role of molecular and phenotypic biomarkers for individualizing treatment decisions in patients with peripheral and cutaneous subtypes
  • Review efficacy and safety data for currently available options for the treatment of patients with PTCL and CTCL
  • Plan strategies for proactively recognizing, monitoring, and managing adverse events associated with treatment of PTCL and CTCL in the frontline setting and beyond
  • Review emerging novel therapies and strategies as well as the latest clinical trial data for the treatment of PTCL and CTCL vely mitigate and manage treatment-related adverse effects that occur with current and emerging approaches, including combination treatment strategies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Steven Horwitz, MD
Steven Horwitz, MD
Associate Member
Department of Medicine
Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Trillium Therapeutics, Verastem, and Vividion Therapeutics; Grant/Research Support: ADC Therapeutics, Affimed, Aileron, Celgene , Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem

Pamela B. Allen, MD, MSc
Pamela B. Allen, MD, MSc
Assistant Professor
Department of Hematology and Medical Oncology
Attending Physician
Bone Marrow and Stem Cell Transplant Center
Emory University Winship Cancer Institute
Atlanta, GA

Disclosures: Consultant: Daichii-Sankyo; Speakers’ Bureau: Curio, Research to Practice

Ahmet Dogan, MD, PhD
Ahmet Dogan, MD, PhD
Chief, Hematopathology Service
Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AbbVie, EUSA Pharma US, Physicians' Education Resource LLC, Seattle Genetics; Grant/Research Support: Roche, Takeda Pharmaceuticals

Neha Mehta-Shah, MD
Neha Mehta-Shah, MD
Assistant Professor
Department of Medicine
Oncology Division
Washington University School of Medicine in St. Louis
St Louis, MO

Disclosures: Consultant: C4 Therapeutics, Daichii-Sanyko, Karyopharm, Kyowa Hakko Kirin Co., Ono; Grant/Institutional Research Support: Bristol Myers Squibb, Celegne, Corvus Pharmaceuticals, Innate, Genentech, Roche, Verastem

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By